Research Interests
Open to PhD applications in the fields of:
- Nanopharmaceuticals
- Metalic/Gold nanoparticles
- Tumour metabolism
- Tumour microenvironment
- Targeted delivery
- Radiopharmaceuticals
- Radiobiology
- Targeted Immunotherapy
Current Research Opportunities
- Developing a controlled release biodegradable platform for nanomedicine delivery
- A microfluidic approach to supressing tumour metabolism and enhancing treatment sensitivity
Public outreach & key achievements
- Prostate Cancer UK funding: https://prostatecanceruk.org/research/research-we-fund/s14-004
- MRC Confidence in Concept – Anti-inflammatory radiosensitising gold nanoparticles for the treatment of prostate cancer
- EPSRC – Nanoengineered microneedle arrays for enhanced plasmonic photothermal therapy of basal cell carcinoma – EP/P034063/1
- EPSRC - Improving patient outcome by integrating the generic with the personal – EPSRC EP/K039342/1
- Research Funder NI overview: https://www.crowdfundinsider.com/tag/dr-jonathan-coulter/
- Materials & Advanced TeChnologies for Healthcare - https://www.qub.ac.uk/schools/SchoolofPharmacy/MATCH/
Research students
| PhD Title | Elevating intracellular oxygen using tumour metabolism suppressing nanoparticles |
| Name | Jie Feng |
| Country | China |
| Year of Study | 2018-2021 |
| PhD Title | PSMA targeted gold nanoparticles as effective prostate cancer radiosensitisers |
| Name | Cancan Yin |
| Country | China |
| Year of Study | 2019-2022 |
| PhD Title | Exploiting hyperactive glucose transporters: a targeting mechanism for drug loaded nanoparticles |
| Name | Tongchuan Wang |
| Country | China |
| Year of Study | 2019-2022 |
| PhD Title | Manipulating tumour metabolism to increase radiation sensitivity |
| Name | Meabh Doherty |
| Country | Northern Ireland |
| Year of Study | 2020-2023 |
Alumni: Where are they now
| PhD Title | Development of a cell cycle computational model predicting outcome to novel nanotherapeutics. |
| Name | Chris Emmerson |
| Year of Study | 2016-2020 |
| Country | Northern Ireland |
| Current Position | Celerion Clinical Trials. Drug interaction data analyst. |
| PhD Title | Enhancing the radiosensitivity of prostate cancer using RALA Gold nano-complexes |
| Name | Lindsey Bennie |
| Year of Study | 2016-2019 |
| Country | Scotland |
| Current Position |
Scientist at pHion Therapeutics working on a project using RALA, a direct consequence of her PhD studies. Lindsey will undertake her PhD viva in November 2019. |
| PhD Title | Radiation induced inflammatory signalling in prostate cancer: A target for co-functionalised gold nanoparticles |
| Name | Dr Natalie Owen |
| Year of Study | 2015-2018 |
| Country | England |
| Current Position | Natalie relocated back to England and was successful in obtaining a Research Scientist position at the prestigious Sanger Institute, Cambridge, England. |
| PhD Title | Dr Shannon O’Neill |
| Name | Enhancing the radiocurability of prostate cancer using the anti-cancer stem cell agent, AD-01, and novel CD44-targeted gold nanoparticles |
| Year of Study | 2015-2018 |
| Country | Northern Ireland |
| Current Position | Shannon is currently working Research scientist at Almac |